Jiang Hao, Jiang Ji, Hu Pei, Hu Yufang
Clinical Pharmacology Research Center, Peking Union Medical College Hospital and Chinese Academy of Medical Sciences, Beijing, PR China.
J Chromatogr B Analyt Technol Biomed Life Sci. 2002 Mar 25;769(1):169-76. doi: 10.1016/s1570-0232(02)00009-0.
A sensitive and specific HPLC-MS-MS method was developed for the determination of endogenous uracil (Ura) and its metabolite dihydrouracil (UH2) in human plasma and urine samples. Plasma samples were extracted with ethyl acetate-isopropanol (85:15, v/v) following added ammonium sulfate, and then separated on a Discovery Amide C16 column with 3% methanol solution as the mobile phase; urine samples were just centrifuged at 2500 g for detection. Quantitation was carried out by LC-MS-MS in the multiple reaction monitoring (MRM) mode. The limits of quantitation of the method for Ura and UH2 were 0.5 and 5 ng ml(-1) (for plasma), and 50 and 100 ng ml(-1) (for urine), respectively. This method can be useful to evaluate the activity of dihydropyrimidine dehydrogenase (DPD), a rate-limiting enzyme of the chemotherapy drug fluoropyrimidine, which will be helpful in investigating subject variation of DPD and adjusting clinical dosage in pyrimidine chemotherapy.
建立了一种灵敏且特异的高效液相色谱-串联质谱法,用于测定人血浆和尿液样本中的内源性尿嘧啶(Ura)及其代谢物二氢尿嘧啶(UH2)。血浆样本在加入硫酸铵后用乙酸乙酯-异丙醇(85:15,v/v)萃取,然后在以3%甲醇溶液为流动相的Discovery Amide C16柱上分离;尿液样本仅以2500 g离心后进行检测。通过液相色谱-串联质谱在多反应监测(MRM)模式下进行定量分析。该方法对Ura和UH2的定量限分别为0.5和5 ng/ml(针对血浆),以及50和100 ng/ml(针对尿液)。该方法可用于评估化疗药物氟嘧啶的限速酶二氢嘧啶脱氢酶(DPD)的活性,这将有助于研究DPD的个体差异并在嘧啶化疗中调整临床剂量。